Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Eur J Pharmacol ; 890: 173611, 2021 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-33017589

RESUMEN

Histamine is a pleiotropic biogenic amine, having affinity towards four distinct histamine receptors. The existing pharmacological studies suggest the usefulness of histamine H4 receptor ligands in the treatment of many inflammatory and immunomodulatory diseases, including allergic rhinitis, asthma, atopic dermatitis, colitis or pruritus. Up to date, several potent histamine H4 receptor ligands were developed, none of which was registered as a drug yet. In this study, a series of potent indole-like and triazine derivatives were tested, in radioligand displacement and functional assays at histamine H4 receptor, as well as in human eosinophils adhesion assay to endothelium. For selected compounds permeability, cytotoxicity, metabolic and in vivo studies were conducted. Adhesion assay differentiated the activity of different groups of compounds with a known affinity towards the histamine H4 receptor. Most of the tested compounds downregulated the number of adherent cells. However, adhesion assay revealed additional properties of tested compounds that had not been detected in radioligand displacement and aequorin-based functional assays. Furthermore, for some tested compounds, these abnormal effects were confirmed during the in vivo studies. In conclusion, eosinophils adhesion assay uncovered pharmacological activity of histamine H4 receptor ligands that has been later confirmed in vivo, underscoring the value of well-suited cell-based phenotypic screening approach in drug discovery.


Asunto(s)
Antiinflamatorios/farmacología , Eosinófilos/metabolismo , Indoles/farmacología , Receptores Histamínicos H4/antagonistas & inhibidores , Triazinas/farmacología , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/metabolismo , Adhesión Celular/efectos de los fármacos , Línea Celular Transformada , Línea Celular Tumoral , Permeabilidad de la Membrana Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Simulación por Computador , Aceite de Crotón/toxicidad , Modelos Animales de Enfermedad , Descubrimiento de Drogas , Evaluación Preclínica de Medicamentos , Edema/inducido químicamente , Edema/tratamiento farmacológico , Células Endoteliales/metabolismo , Eosinófilos/efectos de los fármacos , Humanos , Indoles/administración & dosificación , Indoles/química , Masculino , Ratones , Prurito/inducido químicamente , Prurito/tratamiento farmacológico , Triazinas/administración & dosificación , Triazinas/química , Triazinas/metabolismo
2.
Pharmacol Rep ; 68(6): 1285-1292, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27689756

RESUMEN

BACKGROUND: It has recently been suggested that the adenosine A2A receptor plays a role in several animal models of depression. Additionally, A2A antagonists have reversed behavioral deficits and exhibited a profile similar to classical antidepressants. METHODS: In the present study, imidazo- and pyrimido[2,1-f]purinedione derivatives (KD 66, KD 167, KD 206) with affinity to A2A receptors but poor A1 affinity were evaluated for their antidepressant- and anxiolytic-like activity. The activity of these derivatives was tested using a tail suspension and forced swim test, two widely-used behavioral paradigms for the evaluation of antidepressant-like activity. In turn, the anxiolytic activity was evaluated using the four-plate test. RESULTS: The results showed the antidepressant-like activity of pyrimido- and imidazopurinedione derivatives (i.e. KD 66, KD 167 and KD 206) in acute and chronic behavioral tests in mice. KD 66 revealed an anxiolytic-like effect, while KD 167 increased anxiety behaviors. KD 206 had no effect on anxiety. Furthermore, none of the tested compounds increased locomotor activity. CONCLUSION: Available data support the proposition that the examined compounds with adenosine A2A receptor affinity may be an interesting target for the development of antidepressant and/or anxiolytic agents.


Asunto(s)
Ansiolíticos/metabolismo , Ansiolíticos/uso terapéutico , Antidepresivos/metabolismo , Antidepresivos/uso terapéutico , Purinérgicos/metabolismo , Purinérgicos/uso terapéutico , Animales , Ansiolíticos/química , Antidepresivos/química , Ansiedad/tratamiento farmacológico , Ansiedad/metabolismo , Ansiedad/psicología , Depresión/tratamiento farmacológico , Depresión/metabolismo , Depresión/psicología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Inmovilización/métodos , Inmovilización/psicología , Masculino , Ratones , Purinérgicos/química
3.
Molecules ; 20(8): 13894-912, 2015 Jul 31.
Artículo en Inglés | MEDLINE | ID: mdl-26263963

RESUMEN

Selenium is traditionally considered as an antioxidant element and selenium compounds are often discussed in the context of chemoprevention and therapy. Recent studies, however, have revealed a rather more colorful and diverse biological action of selenium-based compounds, including the modulation of the intracellular redox homeostasis and an often selective interference with regulatory cellular pathways. Our basic activity and mode of action studies with simple selenium and tellurium salts in different strains of Staphylococcus aureus (MRSA) and Saccharomyces cerevisiae indicate that such compounds are sometimes not particularly toxic on their own, yet enhance the antibacterial potential of known antibiotics, possibly via the bioreductive formation of insoluble elemental deposits. Whilst the selenium and tellurium compounds tested do not necessarily act via the generation of Reactive Oxygen Species (ROS), they seem to interfere with various cellular pathways, including a possible inhibition of the proteasome and hindrance of DNA repair. Here, organic selenides are considerably more active compared to simple salts. The interference of selenium (and tellurium) compounds with multiple targets could provide new avenues for the development of effective antibiotic and anticancer agents which may go well beyond the traditional notion of selenium as a simple antioxidant.


Asunto(s)
Diseño de Fármacos , Compuestos de Organoselenio/farmacología , Sales (Química)/farmacología , Selenio/farmacología , Telurio/farmacología , Antiinfecciosos/farmacología , Muerte Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Calcógenos/farmacología , Pruebas de Sensibilidad Microbiana , Compuestos de Organoselenio/química , Oxidación-Reducción , Inhibidores de Proteasoma/farmacología , Especies Reactivas de Oxígeno/metabolismo , Saccharomyces cerevisiae/efectos de los fármacos , Selenio/química , Staphylococcus aureus/citología , Staphylococcus aureus/efectos de los fármacos
4.
Arch Pharm (Weinheim) ; 345(8): 591-7, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22549828

RESUMEN

The study presents novel biological properties of diether derivatives of homo- or substituted piperidine ligands of the histamine H(3) receptor. The compounds were evaluated for their inhibitory potency against acetylcholinesterase (AChE) from the electric eel and butyrylcholinesterase (BuChE) from horse serum. The most interesting multifunctional compound 13 displayed high affinity for the cloned hH(3) R (K(i) = 3.48 nM) and moderate inhibitory potency against both enzymes (IC(50) AChE = 7.91 µM and BuChE = 4.97 µM). Molecular modeling studies revealed interactions with key amino acid residues in the homology model of histamine H(3) receptor ligands, as well as the binding model for AChE and BuChE in the catalytic and peripheral active sites.


Asunto(s)
Inhibidores de la Colinesterasa/farmacología , Éteres/farmacología , Antagonistas de los Receptores Histamínicos/farmacología , Piperidinas/farmacología , Animales , Sitios de Unión , Inhibidores de la Colinesterasa/química , Evaluación Preclínica de Medicamentos/métodos , Electrophorus , Éteres/química , Células HEK293 , Antagonistas de los Receptores Histamínicos/química , Caballos , Humanos , Técnicas In Vitro , Concentración 50 Inhibidora , Modelos Moleculares , Estructura Molecular , Piperidinas/química , Relación Estructura-Actividad
5.
In Vivo ; 26(2): 223-9, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22351662

RESUMEN

AIM: To evaluate a new series of 16 hydantoin derivatives for activity against the intrinsic and overexpressed efflux pumps of the ATTC 25923 Staphylococcus aureus and the clinical Staphylococcus aureus HPV-107 strain, respectively. MATERIALS AND METHODS: The hydantoin compounds were evaluated for activity against the efflux pumps of the ATTC 25923 S. aureus and the clinical S. aureus HPV-107 strains by the aid of the automated ethidium bromide method. Compounds that inhibited the efflux pumps of either strain were evaluated for ability to reduce or reverse resistance of these strains to oxacillin. RESULTS: Although most of the hydantoins inhibited the efflux pumps of the ATTC strain, none reduced the resistance of this strain to oxacillin. In contrast, the inhibition of the Qac efflux pump present in HPV-107 was inhibited to some degree, by much higher concentrations of the hydantoin compounds than that needed for similar activity against the ATTC strain; only hydantoin PI8a significantly reduced the minimum inhibitory concentration of oxacillin against the HPV-107 strain. CONCLUSION: Hydantoin compound PI8a may have potential for therapy of a methicillin-resistant S. aureus infection whose multidrug-resistant phenotype is due to overexpression of an efflux pump.


Asunto(s)
Proteínas Bacterianas/antagonistas & inhibidores , Transporte Biológico/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Hidantoínas/farmacología , Oxacilina/farmacología , Staphylococcus aureus/efectos de los fármacos , Proteínas Bacterianas/metabolismo , Sistemas de Computación , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Etidio/metabolismo , Colorantes Fluorescentes/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/metabolismo , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Oxacilina/metabolismo , Resistencia a las Penicilinas/efectos de los fármacos , Plásmidos/genética , Staphylococcus aureus/metabolismo
6.
In Vivo ; 26(2): 293-7, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22351672

RESUMEN

BACKGROUND: Multidrug resistance (MDR) is one of the major concerns in the treatment of cancer and one of the major causes of therapy failure. The overexpression of an ABC transporter, the ABCB1, is often associated with MDR in cancer. Previously it was observed that hydantoin compounds can modulate the activity of the ABCB1 pump. MATERIALS AND METHODS: Fourteen hydantoin derivatives were synthesized and studied for their capacity to increase accumulation of ethidium bromide (EB) by mouse lymphoma cancer cells that were transfected with the human ABCB1 gene and overexpress the human ABCB1 pump. RESULTS: It was observed that the accumulation of EB by the cells in the presence of four of the newly synthesized hydantoins was strongly increased. Similar but milder effects were also observed for the other seven hydantoins; the remaining three had no activity. CONCLUSION: The 14 hydantoin compounds studied belong to three different structural groups. Structure-activity relationships were studied and important molecular substituents that were possibly responsible for increased the activity of the molecules were identified. This important information may lead to the continuation of our work and to the future synthesis of more active compounds.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Hidantoínas/farmacología , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Animales , Línea Celular Tumoral/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Resistencia a Múltiples Medicamentos/efectos de los fármacos , Etidio/análisis , Etidio/metabolismo , Colorantes Fluorescentes/análisis , Colorantes Fluorescentes/metabolismo , Humanos , Hidantoínas/síntesis química , Hidantoínas/química , Transporte Iónico/efectos de los fármacos , Leucemia L5178/patología , Ratones , Estructura Molecular , Relación Estructura-Actividad , Transfección
7.
Acta Pol Pharm ; 65(1): 65-70, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18536175

RESUMEN

Adenosine A2A receptors belong to the heptaspanning membrane receptors family A, also known as G protein-coupled receptors. In human brain they are highly expressed in striatum, where they co-exist and co-function with adenosine A1, glutamate mGlu5 and dopamine D2 receptors. As glutaminergic neurotransmission modulators in GABAergic enkephalinergic neurons, adenosine A2A receptors are attractive targets for new, alternative therapies of neurodegenerative disorders, like Parkinson's disease and Huntington's disease. The aim of the research was to obtained fluorescently tagged adenosine A2A receptors. Gene encoding human adenosine A2A receptor was inserted into plasmid pEYFP-N1, bearing enhanced yellow fluorescent protein (EYFP). The construct was expressed in HEK 293 cells. Fluorescence was observed by flow cytometry and epifluorescence microscopy. Functional ligand binding properties were investigated by saturation binding analysis of adenosine A2A receptors specific agonist [3H] CGS 21680.


Asunto(s)
Citometría de Flujo/métodos , Perfilación de la Expresión Génica/métodos , Microscopía Fluorescente/métodos , Receptor de Adenosina A2A/genética , Adenosina/análogos & derivados , Adenosina/farmacología , Agonistas del Receptor de Adenosina A2 , Proteínas Bacterianas/metabolismo , Línea Celular , Humanos , Riñón/metabolismo , Ligandos , Proteínas Luminiscentes/metabolismo , Fenetilaminas/farmacología , Plásmidos/metabolismo , Unión Proteica , Ensayo de Unión Radioligante
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA